- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
Patent holdings for IPC class A61P 25/18
Total number of patents in this class: 3394
10-year publication summary
|
111
|
149
|
199
|
241
|
215
|
258
|
279
|
248
|
203
|
87
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2704 |
95 |
| Janssen Pharmaceutica N.V. | 3423 |
64 |
| F. Hoffmann-La Roche AG | 7926 |
63 |
| H. Lundbeck A/S | 1229 |
54 |
| AstraZeneca AB | 2928 |
44 |
| Taisho Pharmaceutical Co., Ltd. | 862 |
42 |
| Glaxo Group Limited | 4132 |
41 |
| Intra-Cellular Therapies, Inc. | 408 |
38 |
| Boehringer Ingelheim International GmbH | 4704 |
36 |
| Pfizer Inc. | 3367 |
33 |
| Sumitomo Dainippon Pharma Co., Ltd. | 216 |
32 |
| Hoffmann-La Roche Inc. | 3379 |
30 |
| Sunovion Pharmaceuticals Inc. | 271 |
28 |
| Astellas Pharma Inc. | 1086 |
26 |
| Sage Therapeutics, Inc. | 362 |
24 |
| Dainippon Sumitomo Pharma Co., Ltd. | 196 |
23 |
| Otsuka Pharmaceutical Co., Ltd. | 1502 |
23 |
| Merck Sharp & Dohme LLC | 3741 |
23 |
| Neurocrine Biosciences, Inc. | 399 |
21 |
| Vanda Pharmaceuticals, Inc. | 352 |
20 |
| Other owners | 2634 |